ASTRO-SITC Joint Session at ASTRO Annual Meeting

When:  Oct 26, 2022 from 12:30 to 13:45 (CT)

Presented by the American Society for Radiation Oncology (ASTRO), in collaboration with the Society for Immunotherapy of Cancer (SITC) the following session will take place during ASTRO's 64th Annual Meeting.

Session Title:
CAR T cell therapy and Radiation Therapy for Hematologic Malignancies: Translating Science from the Lab to the Clinic
Session Description:
Radiation therapy (RT) is a powerful immune modulating agent and when coupled with immune based therapies has the potential to enhance efficacy. While there is a vibrant interest into employing the locoregional and systemic effects of RT combined with cellular therapy, there remains considerable controversy regarding the optimal role for radiation. This education session will provide attendees the opportunity to gain exposure to the rapidly evolving utilization of CAR T cell therapy for patients with non-Hodgkin lymphoma. They will learn about the mechanisms behind CAR T cell therapy as well as practical considerations from an internationally recognized expert hematologic medical oncologist. They will gain insight into the basic science mechanisms underlying the synergistic potential of RT and cellular therapy from one of the few physician scientists in the world investigating RT and CAR T cell therapy for hematologic malignancies. They will learn about existing data, ongoing clinical trials and future clinical trial considerations combining RT and CAR T-cell therapy from an international specialized oncologist whom is PI on an ongoing CAR T-cell clinical trial. Audience members will experience practical learning through a case-based discussion of management considerations for CAR T-cell patients. Radiation therapy can play an important role in combined modality treatments for patients undergoing CAR T-cell therapy in various clinical settings. It is important that clinicians recognize this potential for successful widespread implementation of RT as a tool in this modern era of cellular therapy.

The Current State of CAR T cell Therapy for Patients with Hematologic Malignancies
Sonali Smith, MD - University of Chicago

RT and Cellular Therapy: Mechanisms underlying Synergistic Combined Modality Strategies
Carl DeSelm, MD, PhD - Washington University School of Medicine

Practical Considerations for the Utilization of RT with CAR T cell therapy: The Current State and Beyond
George Mikhaeel, MB ChB, MSc FRCR - King's College London,

Moderator: Chelsea C. Pinnix, MD, PhD - The University of Texas MD Anderson Cancer Center


Henry B. Gonzalez Convention Center
900 E Market St.
San Antonio, TX 78205